1.
Clin Infect Dis
; 69(1): 144-146, 2019 06 18.
Artículo
en Inglés
| MEDLINE
| ID: mdl-30924492
RESUMEN
In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.